Tacrolimus extended-release - Veloxis Pharmaceuticals

Drug Profile

Tacrolimus extended-release - Veloxis Pharmaceuticals

Alternative Names: Envarsus; EnvarsusXR; LCP-Tacro™; MeltDose® tacrolimus tablets; Tacrolimus extended release; Tacrolimus-ER

Latest Information Update: 26 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LifeCycle Pharma
  • Developer Chiesi Farmaceutici; LifeCycle Pharma; University of Kentucky; Veloxis Pharmaceuticals
  • Class Antipsoriatics; Lactones; Macrolides; Skin disorder therapies
  • Mechanism of Action Bone morphogenetic protein receptor type II modulators; Calcineurin inhibitors; Cytokine inhibitors; Immunosuppressants; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal transplant rejection
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Allotransplant rejection; Liver transplant rejection; Renal transplant rejection; Transplant rejection
  • Phase II/III Renal failure
  • Discontinued Autoimmune hepatitis

Most Recent Events

  • 01 Oct 2018 Chiesi Farmaceutici completes the phase I TacroVori drug-drug interaction trial (In volunteers) in Germany (PO) (EudraCT2016-004137-24)
  • 19 Apr 2018 FDA assigns PDUFA action date of 07/01/2019 for Tacrolimus extended release for Renal transplant rejection (Prevention, Treatment-naive)
  • 19 Apr 2018 US FDA accepts sNDA for Tacrolimus extended-release for Renal transplant rejection (Prevention, Treatment-naive) for review
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top